AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service
(NASDAQ:IRTC) SAN FRANCISCO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced results from the Oxford University-led Active Monitoring for AtriaL FIbrillation (AMALFI) randomized clinical trial, presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the Journal of the American Medical Association (JAMA), demonstrating that home-based screening with the Zio® long-term continuous monitoring (LTCM) service led to increased atrial fibrillation (AFib) detection and a shorter time to diagnosis.
Related Questions
How might the increased AFib detection rates from the AMALFI trial affect iRhythm's revenue growth and pricing power?
What are the competitive implications of the Zio® LTCM service versus other wearable ECG monitoring solutions, and could this trial shift market share?
Will the trial results prompt changes in reimbursement or partnership opportunities that could materially impact IRTC's financial outlook?